A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 Following Single Ascending Dose Administration to Healthy Participants
Latest Information Update: 14 Dec 2022
At a glance
- Drugs ION 455 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 07 Dec 2022 Status changed from active, no longer recruiting to completed.
- 23 Sep 2022 Planned End Date changed from 27 Feb 2023 to 9 Nov 2022.
- 23 Sep 2022 Status changed from recruiting to active, no longer recruiting.